Last reviewed · How we verify
Olaparib tablet dosing — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Olaparib tablet dosing (Olaparib tablet dosing) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Olaparib tablet dosing TARGET | Olaparib tablet dosing | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Olaparib tablet dosing CI watch — RSS
- Olaparib tablet dosing CI watch — Atom
- Olaparib tablet dosing CI watch — JSON
- Olaparib tablet dosing alone — RSS
Cite this brief
Drug Landscape (2026). Olaparib tablet dosing — Competitive Intelligence Brief. https://druglandscape.com/ci/olaparib-tablet-dosing. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab